Navigation Links
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
Date:9/11/2007

Will Begin Promotion in October At U.S. Psychiatric Congress

PARSIPPANY, N.J., Sept. 11 /PRNewswire/ -- Validus Pharmaceuticals, Inc. announced today that it has acquired the unique Bipolar Disorder treatment, Equetro(R) (carbamazepine) extended release capsules, from Shire plc.

EQUETRO(R) is a treatment for the acute manic and mixed episodes associated with Bipolar-1 Disorder -- a condition where patients experience extended periods of exaggerated highs in addition to the extended lows commonly associated with Bipolar Disorder. Equetro's patented advanced drug delivery technology also provides patients with the convenience of twice-daily dosing.

"This is a watershed moment in the commercialization of Validus Pharmaceuticals" stated James Hunter, Validus President & CEO. "Equetro(R) provides mental health professionals with an important treatment option in the management of Bipolar Disorder. Equetro(R) also fits well within our growing product portfolio which includes Marplan(R) (isocarboxazid), the classic MAO- inhibitor for treatment-resistant depression."

Validus Pharmaceuticals will begin active promotion of Equetro(R) during the U.S. Psychiatric & Mental Health Congress -- one of the nation's largest gatherings of mental health professionals -- in Orlando, FL in early October.

About Validus Pharmaceuticals:

Validus Pharmaceuticals is a specialty pharmaceutical company founded in Parsippany, NJ in 2007 to serve the unmet needs of patients with central nervous system (CNS) diseases. The company pursues this mission with targeted and focused marketing efforts and active acquisition and in-licensing programs aimed at underutilized CNS products that have important future potential. Validus is a portfolio company of the Konanda Pharma Fund I, L.P. in New York City. Please log-on to http://www.validuspharma.com for additional information.

About Marplan(R)

Please go to the Marplan(R) website http://www.marplan.com for Full Prescribing Information, including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO-inhibitors are contraindicated with certain drugs, and potential hypertensive crises may occur with tyramine containing foods. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially within the first few months of therapy.

About Equetro(R)

Please see complete Prescribing Information for Equetro at http://www.equetro.com. EQUETRO(R) contains carbamazepine. If you are currently taking another medication that contains carbamazepine, do not begin taking Equetro(R) without discussing this with your healthcare provider. Products that contain carbamazepine have been associated with rare but serious types of blood disorders. People with Bipolar Disorder have an increased risk for suicide. It is important to discuss risk factors for suicide with your healthcare provider.

About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is an investment fund that is managed by Konanda Pharma Partners, LLC, based in New York City. The Fund acquires mature branded drugs through portfolio companies which it owns and operates. Please log-on to http://www.konanda.com for additional information.


'/>"/>
SOURCE Validus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF expands license agreement with Advanced Cell Technology
4. Verizon expands broadband service in Wisconsin
5. Bandwidth provider expands in Milwaukee
6. Wisconsins biodiesel network expands
7. Quad/Graphics expands reach in western states
8. University of South Florida expands GE Healthcare relationship
9. Metavante expands healthcare payments division
10. Fiserv expands services to health plan market
11. Bone Care expands patent protection of core drug offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a complex biological network, a depiction of a system of linkages and ... Dmitry Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
Breaking Biology Technology:
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
Breaking Biology News(10 mins):